Niannian Ji

Dr. Niannian Ji

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2021 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
NJNiannian Ji
Niannian Ji
NMNeelam Mukherjee
Neelam Mukherjee
ZSZhen-Ju Shu
Zhen-Ju Shu
RRRyan M. Reyes
Ryan M. Reyes
JMJoshua J. Meeks
Joshua J. Meeks
RSRobert S Svatek
Robert S Svatek
Bacillus Calmette-Guérin (BCG) is the most effective intravesical agent at reducing recurrence for patients with high-grade, non–muscle-invasive bladder cancer. Nevertheless, response to BCG is variable and strategies to boost BCG efficacy have not materialized. Prior work demonstrated a requirement for either conventional αβ or nonconventional γδ T cells in mediating BCG treatment efficacy, yet the importance of T-cell antigen specificity for BCG's treatment effect is unclear. Here, we provide direct evidence to show that BCG increases the number of tumor antigen–specific αβ T cells in patients with bladder cancer and protects mice from subsequent same-tumor challenge, supporting BCG induction of tumor-specific memory and protection. Adoptive T-cell transfers of antigen-specific αβ T cells into immunodeficient mice challenged with syngeneic MB49 bladder tumors showed that both tumor and BCG antigen–specific αβ T cells contributed to BCG efficacy. BCG-specific antitumor immunity, however, also required nonconventional γδ T cells. Prior work shows that the mTOR inhibitor rapamycin induces the proliferation and effector function of γδ T cells. Here, rapamycin increased BCG efficacy against both mouse and human bladder cancer in vivo in a γδ T cell–dependent manner. Thus, γδ T cells augment antitumor adaptive immune effects of BCG and support rapamycin as a promising approach to boost BCG efficacy in the treatment of non–muscle-invasive bladder cancer.

1 May 2007 in Expert Review of Clinical Immunology
Verified
Journal Article
Open access
TFThomas G Forsthuber
Thomas G Forsthuber
NJNiannian Ji
Niannian Ji

1 March 2011 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
NJNiannian Ji
Niannian Ji
NRNagarjun Rao
Nagarjun Rao
NGNeal M. Guentzel
Neal M. Guentzel
BABernard P. Arulanandam
Bernard P. Arulanandam
TFThomas G. Forsthuber
Thomas G. Forsthuber
Ab-mediated blockade of the adhesion molecule VLA-4 has been shown to ameliorate disease in human multiple sclerosis patients and experimental autoimmune encephalomyelitis (EAE) animal models. We wanted to determine whether anti–VLA-4 Ab treatment affected the function and persistence of autoreactive T cells in mice with EAE. Unexpectedly, we observed a high level of mortality in anti–VLA-4 mAb (PS/2)-treated mice with actively induced EAE despite decreased disease severity. Investigation of the underlying mechanism showed that injection of PS/2 mAb in combination with pertussis toxin resulted in anaphylaxis and mortality. Furthermore, the data showed that CD4+ T cells were required for this effect and suggested a role for IL-1β and TNF-α in the underlying pathology. The results reveal a previously not appreciated deleterious effect of anti–VLA-4 Ab treatment in combination with exposure to pertussis toxin.

21 May 2021 in Cellular Immunology
Verified
Journal Article
Closed access
CHCarol Chase Huizar
Carol Chase Huizar
NJNiannian Ji
Niannian Ji
RRRobert Reddick
Robert Reddick
GOGary Ostroff
Gary Ostroff
TFThomas G. Forsthuber
Thomas G. Forsthuber

27 May 2025 in Neoplasia
Verified
Journal Article
Open access
ZHZaineb Hassouneh
Zaineb Hassouneh
ONOnika D.V. Noel
Onika D.V. Noel
NJNiannian Ji
Niannian Ji
MKMichelle E. Kim
Michelle E. Kim
NBNatalia Bowman
Natalia Bowman
NMNeelam Mukherjee
Neelam Mukherjee
Bladder cancer (BCa) exhibits favorable responses to immunotherapy, but a significant percentage of patients fail to show a response owing to an inadequate tumor-immune landscape. We previously showed that NK cells are one of the predominant tumor-infiltrating lymphocytes in BCa and correlate with improved patient survival. However, that link was observed only with CD56bright NK cells while the CD56dim subset exhibited reduced cytotoxicity and higher accumulation in advanced BCa stages. The role of CD56 in NK cell functionality in BCa, however, remains unclear. Using flow cytometry and cytotoxicity assays, we demonstrated a significant decrease in cytotoxicity and activation of NK92 cells against BCa upon CD56 deletion. Further, migration assays and atomic force microscopy showed CD56 deletion impaired NK92 cell migration and adhesion to bladder tumor cells, reducing NK92 cell-mediated apoptosis of BCa cells. Prolonged exposure to bladder tumors led to CD56 loss in NK92 cells, suggesting tumor-induced NK92 cell dysfunction via CD56 reduction, consistent with our previous findings. Confocal microscopy revealed an overlap of CD56 and phosphorylated Pyk2, a critical kinase at the tumor-immune synapse, potentially mediating the downstream cytotoxicity effects. Blocking Pyk2 phosphorylation decreased CD56-mediated NK92 cell activation and reduced NK92 cell-mediated cytotoxicity against BCa. Finally, we showed that CD56 is also expressed by BCa cells and may be a predictive biomarker for NK cell-based immunotherapy, with its shedding indicating a mechanism for NK cell evasion. Our study identifies a novel innate-immune axis in BCa, leading to a better understanding of intratumoral NK cell biology and advancing NK cell-targeted treatments.

19 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ZHZaineb Hassouneh
Zaineb Hassouneh
ONOnika D. V. Noel
Onika D. V. Noel
NJNiannian Ji
Niannian Ji
MKMichelle E. Kim
Michelle E. Kim
JSJordan Svatek
Jordan Svatek
NMNeelam Mukherjee
Neelam Mukherjee
Despite its immunogenic nature, bladder cancer (BCa) responds sub-optimally to FDA-approved immunotherapy. Background/Objectives: We have previously shown that natural killer (NK) cells are major contributors to overall patient survival in BCa. In our efforts to identify clinically approved agents that enhance NK cell activation, we identified eribulin, a microtubule destabilizer primarily used in breast cancer. Ongoing clinical trials are investigating the potential integration of eribulin into the standard of care in BCa; however, the mechanistic rationale for these trials remains unclear. Methods: Here, we explore the effects of low-dose eribulin on direct NK cell activation in vitro, including on primary patient samples, and in vivo utilizing multiple murine models. Flow cytometry and RNA sequencing were employed to identify the mechanism of NK cell activation by eribulin, which was associated with increased migration and cytotoxicity of NK cells against BCa cells. Results: We found that localized eribulin instillation significantly reduces bladder tumor burden and improves survival in primary BCa in an NK cell-dependent manner. Importantly, eribulin promoted the shift of patient-derived intratumoral NK cells towards an anti-tumor CD49a+ CD103+ NK subset (ieILC1-like) while diminishing the dysfunctional NR4A2-expressing CD49a− NK subset. Moreover, it decreased the overall expression of exhaustion markers on NK cells, a pattern replicated in our murine models. Conclusions: These findings are paradigm-shifting given that chemotherapy is traditionally considered immunosuppressive. Our study reveals the novel effect of low-dose eribulin chemotherapy in inhibiting bladder tumor growth by enhancing anti-tumor NK cell immunity, challenging previous assumptions and opening new therapeutic approaches to improve antitumor immunity.